May 25, 2020 | Biotechnology & Pharmaceuticals
Laura Shawver was the ex-CEO of Synthorx Inc, which was bought out by Sanofi for USD2.5bn.
After an USD88m payout, she has joined Silverback Therapeutics as CEO.
Silverback Therapeutics is working on a next-gen antibody drug conjugate. Laura is now in charge of steering that program to the clinic, where it will be tested in HER2 positive cancers.
Copyright © Track Record